May 9 |
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates
|
May 9 |
Intellia Therapeutics GAAP EPS of -$1.12 beats by $0.25, revenue of $28.94M beats by $19.87M
|
May 9 |
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
|
May 8 |
Intellia Therapeutics Q1 2024 Earnings Preview
|
May 8 |
Just Say No to Drugs: 3 Pharma Stocks to Avoid
|
May 3 |
Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
|
May 3 |
Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street’s Radar
|
May 3 |
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
May 2 |
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
|
May 2 |
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
|